Neogen Announces Third Quarter Results
Neogen Corporation (NEOG) reported third-quarter revenues of $128.2 million, marking a 10% year-over-year increase, with year-to-date revenues up 14%. Net income for the quarter was $5.4 million, adversely affected by $10.6 million in costs related to the merger with 3M's Food Safety business. Gross margins decreased to 44.8%, impacted by rising raw material costs and a shift toward lower-margin products. Both Food Safety and Animal Safety segments experienced revenue growth, while international revenues rose 10%, though China saw a 17% decline due to COVID-19 restrictions.
- Third-quarter revenues increased 10% year-over-year to $128.2 million.
- Year-to-date revenues rose 14% to $387.1 million.
- Food Safety segment revenues grew 7% to $62.8 million, driven by new product sales.
- Animal Safety segment revenues increased 12% to $65.5 million, led by strong veterinary instrument sales.
- International revenues rose 10%, with U.K. operations up 16%.
- Net income of $5.4 million was impacted by $10.6 million in merger-related costs.
- Gross margins fell to 44.8% from 46.1% due to rising raw material costs and a shift to lower-margin products.
- China's revenues decreased by 17% due to COVID-19 lockdowns and poor economic conditions.
Solid year-over-year revenue growth showcases continued strength of products and markets
Closing of announced agreement to merge with 3M's Food Safety business on track and company has made strong progress with integration plans
LANSING, Mich., March 24, 2022 /PRNewswire/ -- Neogen Corporation (NASDAQ: NEOG) announced today the results of the third quarter of its 2022 fiscal year, which ended February 28. Revenues were
"I am pleased to report solid top line growth for the quarter, with meaningful gains across our Food Safety, Animal Safety, and international operations," said John Adent, Neogen's President and Chief Executive Officer. "Our results for the third quarter demonstrate the resilience of our business, particularly in an inflationary environment and amid continued supply chain disruptions. We are making significant progress with integration planning in anticipation of the closing of our transaction with 3M's Food Safety business, a deal that positions us at the forefront of this new era in food security with the resources, capabilities, and solutions to be a global food security provider."
Net income for the third quarter was
Current year-to-date net income was
For each comparative period above, earnings per share amounts have been adjusted to reflect the company's 2-for-1 stock split on June 4, 2021.
Gross margins were
Excluding the 3M Food Safety related deal costs, operating expenses rose by
"We incurred significant legal and consulting fees during the quarter as we prepared for the 3M Food Safety combination; this spending will continue through the end of this fiscal year and into next fiscal year as we work toward closing," said Steve Quinlan, Neogen's Chief Financial Officer. "At the same time, our team is also continuing to drive growth initiatives across the company while addressing the current cost pressures in our business."
Food Safety
Revenues for the company's Food Safety segment were
Additional growth in this segment came from the company's diagnostics portfolio, with increases in allergen test kits (
Animal Safety
Revenues for the company's Animal Safety segment were
Biosecurity products sold through the Animal Safety segment increased by
Neogen's worldwide genomics business recorded an increase of
International revenues rose by
In China, revenues decreased by
Neogen Corporation develops and markets comprehensive solutions dedicated to food and animal safety. The company's Food Safety segment markets dehydrated culture media and diagnostic test kits to detect foodborne bacteria, natural toxins, food allergens, drug residues, plant diseases, and sanitation concerns. Neogen's Animal Safety segment is a leader in the development of genomic solutions along with the manufacturing and distribution of a variety of animal healthcare products, including diagnostics, pharmaceuticals, veterinary instruments, wound care, and disinfectants, as well as rodent and insect control solutions.
Certain portions of this news release that do not relate to historical financial information constitute forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties. Actual future results and trends may differ materially from historical results or those expected depending on a variety of factors listed in Management's Discussion and Analysis of Financial Condition and Results of Operations in the company's most recently filed Form 10-K.
NEOGEN CORPORATION UNAUDITED SUMMARIZED CONSOLIDATED OPERATING DATA (In thousands, except for per share and percentages) | ||||||||||||
Quarter ended Feb. 28 | 9 Months ended Feb. 28 | |||||||||||
2022 | 2021 | 2022 | 2021 | |||||||||
Revenue | ||||||||||||
Food Safety | $ | 62,756 | $ | 58,424 | $ | 192,610 | $ | |||||
Animal Safety | 65,488 | 58,285 | 194,456 | 170,891 | ||||||||
Total revenue | 128,244 | 116,709 | 387,066 | 341,034 | ||||||||
Cost of sales | 70,832 | 62,860 | 209,052 | 183,669 | ||||||||
Gross margin | 57,412 | 53,849 | 178,014 | 157,365 | ||||||||
Operating expenses | ||||||||||||
Sales & marketing | 21,477 | 18,693 | 63,220 | 52,938 | ||||||||
Administrative | 24,997 | 15,146 | 60,985 | 38,343 | ||||||||
Research & development | 4,561 | 4,236 | 13,218 | 12,170 | ||||||||
Total operating expenses | 51,035 | 38,075 | 137,423 | 103,451 | ||||||||
Operating income | 6,377 | 15,774 | 40,591 | 53,914 | ||||||||
Other income | 266 | 203 | 707 | 1,208 | ||||||||
Income before tax | 6,643 | 15,977 | 41,298 | 55,122 | ||||||||
Income tax | 1,200 | 2,600 | 7,950 | 10,000 | ||||||||
Net income | $ | 5,443 | $ | 13,377 | $ | 33,348 | $ | 45,122 | ||||
Net income per diluted share | $ | $ | $ | $ | ||||||||
Other information: | ||||||||||||
Shares to calculate per share | 108,133 | 107,390 | 108,130 | 106,768 | ||||||||
Depreciation & amortization | $ | 6,322 | $ | 5,633 | $ | 17,833 | $ | 15,107 | ||||
Interest income | 314 | 294 | 741 | 1,571 | ||||||||
Gross margin (% of sales) | ||||||||||||
Operating income (% of sales) | ||||||||||||
Revenue increase vs. FY 2021 | ||||||||||||
Net income vs. FY 2021 | ( | ( |
NEOGEN CORPORATION UNAUDITED SUMMARIZED CONSOLIDATED BALANCE SHEET DATA (In thousands) | |||||
Feb. 28 | May 31 | ||||
2022 | 2021 | ||||
Assets | |||||
Current assets | |||||
Cash & investments | $ | 378,439 | $ | 381,087 | |
Accounts receivable | 92,978 | 91,823 | |||
Inventory | 113,395 | 100,701 | |||
Other current assets | 23,514 | 17,840 | |||
Total current assets | 608,326 | 591,451 | |||
Property & equipment, net | 104,699 | 100,453 | |||
Goodwill & other assets | 266,873 | 228,288 | |||
Total assets | $ | 979,898 | $ | 920,192 | |
Liabilities & Equity | |||||
Current liabilities | $ | 64,403 | $ | 53,599 | |
Non-current liabilities | 39,951 | 26,216 | |||
Equity: Shares outstanding 107,818 at Feb. 28, & 107,468 at May 31 | 875,544 | 840,377 | |||
Total liabilities & equity | $ | 979,898 | $ | 920,192 |
CONTACT: Steve Quinlan, Chief Financial Officer
517.372.9200, squinlan@neogen.com
View original content:https://www.prnewswire.com/news-releases/neogen-announces-third-quarter-results-301509892.html
SOURCE NEOGEN Corporation
FAQ
What were Neogen's revenues for the third quarter of fiscal year 2022?
How much did Neogen's net income decrease due to merger costs?
What impact did COVID-19 have on Neogen's international revenues?
What growth did Neogen's Animal Safety segment experience in Q3 2022?